These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 30192094)

  • 21. Tardive Dyskinesia: Treatment Update.
    Arya D; Khan T; Margolius AJ; Fernandez HH
    Curr Neurol Neurosci Rep; 2019 Aug; 19(9):69. PubMed ID: 31420757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.
    Tandon R; Belmaker RH; Gattaz WF; Lopez-Ibor JJ; Okasha A; Singh B; Stein DJ; Olie JP; Fleischhacker WW; Moeller HJ;
    Schizophr Res; 2008 Mar; 100(1-3):20-38. PubMed ID: 18243663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship of pharmacology to side effects.
    Casey DE
    J Clin Psychiatry; 1997; 58 Suppl 10():55-62. PubMed ID: 9265918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical management of tardive dyskinesia: Five steps to success.
    Citrome L
    J Neurol Sci; 2017 Dec; 383():199-204. PubMed ID: 29246613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-acting injectable antipsychotics in the elderly: guidelines for effective use.
    Masand PS; Gupta S
    Drugs Aging; 2003; 20(15):1099-110. PubMed ID: 14651433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spontaneous and drug-induced movement disorders in schizophrenia.
    Kopala LC
    Acta Psychiatr Scand Suppl; 1996; 389():12-7. PubMed ID: 8985472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical risk factors for the development of tardive dyskinesia.
    Solmi M; Pigato G; Kane JM; Correll CU
    J Neurol Sci; 2018 Jun; 389():21-27. PubMed ID: 29439776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reprint of: Clinical management of tardive dyskinesia: Five steps to success.
    Citrome L
    J Neurol Sci; 2018 Jun; 389():61-66. PubMed ID: 29519687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The treatment of tardive dyskinesia and tardive dystonia.
    Simpson GM
    J Clin Psychiatry; 2000; 61 Suppl 4():39-44. PubMed ID: 10739330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcium channel blockers for neuroleptic-induced tardive dyskinesia.
    Essali A; Deirawan H; Soares-Weiser K; Adams CE
    Cochrane Database Syst Rev; 2011 Nov; (11):CD000206. PubMed ID: 22071797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Managing antipsychotic-induced tardive dyskinesia.
    Gardos G
    Drug Saf; 1999 Feb; 20(2):187-93. PubMed ID: 10082074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Assessment and Treatment of Antipsychotic-Induced Akathisia.
    Pringsheim T; Gardner D; Addington D; Martino D; Morgante F; Ricciardi L; Poole N; Remington G; Edwards M; Carson A; Barnes TRE
    Can J Psychiatry; 2018 Nov; 63(11):719-729. PubMed ID: 29685069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.
    Bergman H; Rathbone J; Agarwal V; Soares-Weiser K
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD000459. PubMed ID: 29409162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intermittent drug techniques for schizophrenia.
    Sampson S; Mansour M; Maayan N; Soares-Weiser K; Adams CE
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD006196. PubMed ID: 23881657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.
    De Berardis D; Rapini G; Olivieri L; Di Nicola D; Tomasetti C; Valchera A; Fornaro M; Di Fabio F; Perna G; Di Nicola M; Serafini G; Carano A; Pompili M; Vellante F; Orsolini L; Martinotti G; Di Giannantonio M
    Ther Adv Drug Saf; 2018 May; 9(5):237-256. PubMed ID: 29796248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia.
    Barnes TR
    Psychiatr Dev; 1987; 5(4):301-19. PubMed ID: 2895467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schizophrenic patients?
    Levin H; Chengappa KN; Kambhampati RK; Mahdavi N; Ganguli R
    J Clin Psychiatry; 1992 Jul; 53(7):248-51. PubMed ID: 1353492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia.
    Bergman H; Walker DM; Nikolakopoulou A; Soares-Weiser K; Adams CE
    Health Technol Assess; 2017 Aug; 21(43):1-218. PubMed ID: 28812541
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.